MCID: UTR033
MIFTS: 44

Uterine Corpus Cancer

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Uterine Corpus Cancer

MalaCards integrated aliases for Uterine Corpus Cancer:

Name: Uterine Corpus Cancer 12 15 17 70
Malignant Uterine Corpus Neoplasm 70
Corpus Uteri Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9460
ICD9CM 34 182
NCIt 50 C3556
SNOMED-CT 67 93718007
ICD10 32 C54 C54.9
UMLS 70 C0153574 C1883486

Summaries for Uterine Corpus Cancer

Disease Ontology : 12 A uterine cancer that is located in the uterine corpus.

MalaCards based summary : Uterine Corpus Cancer, also known as malignant uterine corpus neoplasm, is related to uterine corpus endometrial carcinoma and endometrial serous adenocarcinoma. An important gene associated with Uterine Corpus Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Gene Expression and ERK Signaling. Affiliated tissues include uterine corpus, breast and lung, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Uterine Corpus Cancer

Diseases related to Uterine Corpus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 388)
# Related Disease Score Top Affiliating Genes
1 uterine corpus endometrial carcinoma 31.7 U2AF1 TP53 SLC25A16 PTEN PPP2R1A POLE
2 endometrial serous adenocarcinoma 31.4 TP53 PTEN PPP2R1A POLE PIK3CA KRAS
3 endometrial cancer 31.2 TP53 S100A6 PTEN PPP2R1A POLE PIK3CA
4 uterine body mixed cancer 31.2 U2AF1 TP53 SLC25A16 PTEN PPP2R1A POLE
5 clear cell adenocarcinoma 30.6 TP53 PIK3CA ARID1A
6 adenosquamous carcinoma 30.5 TP53 PTEN PIK3CA KRAS
7 papillary serous adenocarcinoma 30.5 TP53 KRAS HRAS BRCA1
8 sarcoma 30.3 TP53 PIK3CA MYC KRAS HRAS CTNNB1
9 cervical cancer 30.0 U2AF1 TP53 PTEN PIK3CA MYC HRAS
10 bladder cancer 30.0 TP53 PTEN PIK3CA MYC MIR10B KRAS
11 serous cystadenocarcinoma 29.7 TP53 PTEN PPP2R1A POLE PIK3CA MIR10B
12 uterine corpus sarcoma 11.2
13 mixed endometrial stromal and smooth muscle tumor 11.1
14 anal carcinoma in situ 10.5 TP53 MYC
15 gastric papillary adenocarcinoma 10.5 TP53 ERBB2
16 thyroid hurthle cell adenoma 10.5 PTEN PIK3CA
17 vulva basal cell carcinoma 10.5 MYC ERBB2
18 glassy cell carcinoma of the cervix 10.5 ESR1 ERBB2
19 bartholin's gland adenoma 10.5 TP53 ESR1
20 bartholin's gland benign neoplasm 10.5 TP53 ESR1
21 breast intraductal papillomatosis 10.5 ESR1 ERBB2
22 vestibular gland benign neoplasm 10.5 TP53 ESR1
23 nipple carcinoma 10.5 ESR1 ERBB2
24 hepatic flexure cancer 10.5 KRAS HRAS
25 apocrine adenosis of breast 10.5 TP53 ERBB2
26 breast squamous cell carcinoma 10.5 TP53 ERBB2
27 clear cell adenofibroma 10.5 PPP2R1A PIK3CA ARID1A
28 myoepithelial carcinoma 10.5 TP53 PIK3CA HRAS
29 vulvar intraepithelial neoplasia 10.5 TP53 CTNNB1
30 esophagus adenocarcinoma 10.5 TP53 MYC ERBB2
31 parameningeal embryonal rhabdomyosarcoma 10.5 TP53 PIK3CA FBXW7
32 basaloid lung carcinoma 10.5 TP53 BRCA1
33 gallbladder adenocarcinoma 10.5 TP53 PIK3CA ERBB2
34 neurofibroma 10.5 TP53 PTEN ERBB2
35 trachea carcinoma in situ 10.5 KRAS HRAS
36 signet ring basal cell carcinoma 10.5 KRAS HRAS
37 cobblestone retinal degeneration 10.5 KRAS HRAS
38 comedo carcinoma 10.5 TP53 ESR1 ERBB2
39 familiar ovarian carcinoma 10.5 PIK3CA BRCA1
40 monoclonal gammopathy of uncertain significance 10.5 U2AF1 TP53 MYC
41 breast malignant phyllodes tumor 10.5 TP53 ESR1 ERBB2
42 anal squamous cell carcinoma 10.5 TP53 PIK3CA FBXW7
43 lung oat cell carcinoma 10.5 TP53 PTEN PIK3CA
44 primary peritoneal carcinoma 10.5 TP53 ERBB2 BRCA1
45 pancreatic signet ring cell adenocarcinoma 10.5 TP53 KRAS HRAS
46 prostate squamous cell carcinoma 10.5 TP53 PIK3CA HRAS
47 frontal lobe neoplasm 10.5 TP53 MYC
48 immature teratoma of ovary 10.5 KRAS HRAS
49 ovarian clear cell adenofibroma 10.5 PTEN PIK3CA KRAS
50 breast scirrhous carcinoma 10.5 ESR1 ERBB2

Graphical network of the top 20 diseases related to Uterine Corpus Cancer:



Diseases related to Uterine Corpus Cancer

Symptoms & Phenotypes for Uterine Corpus Cancer

GenomeRNAi Phenotypes related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

26 (show top 50) (show all 54)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.7 HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.7 HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.7 KRAS
4 Decreased viability GR00106-A-0 10.7 KRAS
5 Decreased viability GR00221-A-1 10.7 ESR1 HRAS KRAS PIK3CA MYC
6 Decreased viability GR00221-A-2 10.7 BRCA1 ESR1 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.7 BRCA1 HRAS MYC
8 Decreased viability GR00221-A-4 10.7 ESR1 PIK3CA
9 Decreased viability GR00249-S 10.7 MYC
10 Decreased viability GR00301-A 10.7 BRCA1 KRAS
11 Decreased viability GR00381-A-1 10.7 KRAS
12 Decreased viability GR00386-A-1 10.7 ESR1
13 Decreased viability GR00402-S-2 10.7 ESR1 PIK3CA MYC
14 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.14 POLE
15 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.14 KRAS
16 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.14 FBXW7
17 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.14 FBXW7
18 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.14 POLE
19 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.14 BRCA1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-139 10.14 BRCA1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.14 PTEN
22 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.14 PTEN
23 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.14 ERBB2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.14 ARID1A BRCA1 ERBB2 POLE PTEN
25 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.14 ARID1A
26 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.14 FBXW7
27 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.14 ARID1A
28 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.14 ARID1A
29 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.14 HRAS
30 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.14 POLE
31 Increased shRNA abundance (Z-score > 2) GR00366-A-204 10.14 BRCA1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.14 ERBB2 POLE
33 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.14 BRCA1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.14 ARID1A
35 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.14 PTEN
36 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.14 KRAS
37 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.14 HRAS
38 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.14 ERBB2 POLE
39 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.14 PTEN
40 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.14 ARID1A
41 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.14 FBXW7
42 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.14 ERBB2
43 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.14 ERBB2 KRAS POLE PTEN
44 Increased shRNA abundance (Z-score > 2) GR00366-A-66 10.14 PTEN
45 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.14 ARID1A
46 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.14 H2AC18
47 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.14 HRAS
48 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.14 ERBB2 POLE
49 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.14 HRAS ERBB2 POLE PTEN
50 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.14 POLE

MGI Mouse Phenotypes related to Uterine Corpus Cancer:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 ARID1A BRCA1 CHD4 CTNNB1 ERBB2 ESR1
2 homeostasis/metabolism MP:0005376 10.38 ARID1A BRCA1 CTNNB1 ERBB2 ESR1 FBXW7
3 mortality/aging MP:0010768 10.38 ARID1A BRCA1 CHD4 CTNNB1 ERBB2 ESR1
4 cellular MP:0005384 10.37 ARID1A BRCA1 CHD4 CTNNB1 ERBB2 ESR1
5 endocrine/exocrine gland MP:0005379 10.37 ARID1A BRCA1 CHD4 CTNNB1 ERBB2 ESR1
6 growth/size/body region MP:0005378 10.36 ARID1A BRCA1 CTNNB1 ERBB2 ESR1 FBXW7
7 embryo MP:0005380 10.35 ARID1A BRCA1 CHD4 CTNNB1 ERBB2 ESR1
8 immune system MP:0005387 10.3 ARID1A BRCA1 CHD4 CTNNB1 ESR1 FBXW7
9 integument MP:0010771 10.29 BRCA1 CTNNB1 ERBB2 ESR1 FBXW7 HRAS
10 neoplasm MP:0002006 10.28 ARID1A BRCA1 CTNNB1 ERBB2 ESR1 FBXW7
11 digestive/alimentary MP:0005381 10.27 BRCA1 CTNNB1 ERBB2 ESR1 FBXW7 HRAS
12 muscle MP:0005369 10.2 ARID1A BRCA1 CTNNB1 ERBB2 ESR1 HRAS
13 craniofacial MP:0005382 10.19 ARID1A CTNNB1 ERBB2 FBXW7 HRAS KRAS
14 nervous system MP:0003631 10.18 ARID1A BRCA1 CTNNB1 ERBB2 ESR1 FBXW7
15 limbs/digits/tail MP:0005371 10.1 BRCA1 CTNNB1 ERBB2 ESR1 KRAS MYC
16 normal MP:0002873 10.1 ARID1A BRCA1 CTNNB1 ERBB2 ESR1 FBXW7
17 no phenotypic analysis MP:0003012 10.02 ARID1A CHD4 CTNNB1 ESR1 HRAS KRAS
18 reproductive system MP:0005389 9.85 ARID1A BRCA1 CTNNB1 ERBB2 ESR1 KRAS
19 pigmentation MP:0001186 9.73 BRCA1 CTNNB1 KRAS MYC PTEN TP53
20 respiratory system MP:0005388 9.61 BRCA1 CTNNB1 ERBB2 ESR1 FBXW7 HRAS
21 skeleton MP:0005390 9.36 ARID1A BRCA1 CTNNB1 ERBB2 ESR1 HRAS

Drugs & Therapeutics for Uterine Corpus Cancer

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 The Effectiveness of a Comprehensive Physical Activity Behavioral Intervention on Underserved Diverse Obese Endometrial Cancer Survivors Completed NCT02575872
2 The Relationship of Racial Genetic Admixture With Endometrial Cancer Outcomes Not yet recruiting NCT01198171

Search NIH Clinical Center for Uterine Corpus Cancer

Genetic Tests for Uterine Corpus Cancer

Anatomical Context for Uterine Corpus Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Uterine Corpus Cancer:

19
Uterine Corpus

MalaCards organs/tissues related to Uterine Corpus Cancer:

40
Breast, Lung, Bone, Ovary, Thyroid, Colon, Skin

Publications for Uterine Corpus Cancer

Articles related to Uterine Corpus Cancer:

(show top 50) (show all 136)
# Title Authors PMID Year
1
A national surveillance study of the current status of reirradiation using brachytherapy in Japan. 61
32888854 2021
2
Clinical and histopathologic analysis of gynecological cancer: a single institute experience over 7 years. 61
32131080 2020
3
Major clinical research advances in gynecologic cancer in 2019. 61
32319232 2020
4
Hyaluronic acid gel injection in rectovaginal septum reduced incidence of rectal bleeding in brachytherapy for gynecological malignancies. 61
31879238 2020
5
Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial. 61
31348579 2019
6
Beyond Obesity: The Rising Incidence and Mortality Rates of Uterine Corpus Cancer. 61
31232669 2019
7
Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers. 61
31116674 2019
8
Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. 61
30733056 2019
9
Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000-2014. 61
29795414 2018
10
Secondary Breast, Ovarian, and Uterine Cancers After Colorectal Cancer: A Nationwide Population-Based Cohort Study in Korea. 61
30239394 2018
11
Advancing Uterine Cancer Survivorship Among African American Women. 61
30126566 2018
12
The bidirectional association among female hormone-related cancers: breast, ovary, and uterine corpus. 61
29659167 2018
13
Major clinical research advances in gynecologic cancer in 2017. 61
29468855 2018
14
Enhancement of Uterine Cancer Development after Oocyte Depletion by Juvenile Exposure 
to Gamma Radiation in Rats: - A Comparative Study on Sensitivity of Damage to 
Female Reproductive Organs by Radiation 
between Juvenile and Adulthood Using a Rat Model. 61
32231939 2017
15
Survival of Cancer Patients in Northeast China: Analysis of Sampled Cancers from Population-Based Cancer Registries. 61
28161932 2017
16
Need for an up to date and comprehensive risk factor analysis to determine the lifetime risk of uterine corpus cancer in Taiwan women. 61
28805629 2017
17
Reply to "Need for an up to date and comprehensive risk factor analysis to determine the lifetime risk of uterine corpus cancer in Taiwan women". 61
28805626 2017
18
Major clinical research advances in gynecologic cancer in 2016: 10-year special edition. 61
28382802 2017
19
Gemella morbillorum bacteremia following total laparoscopic hysterectomy for uterine corpus cancer. 61
30254882 2017
20
Incidence and lifetime risk of uterine corpus cancer in Taiwanese women from 1991 to 2010. 61
28254229 2017
21
Laparoscopic Repair of Vaginal Evisceration after Abdominal Hysterectomy for Uterine Corpus Cancer: A Case Report and Literature Review. 61
28502966 2017
22
High lncRNA H19 expression as prognostic indicator: data mining in female cancers and polling analysis in non-female cancers. 61
27926484 2017
23
Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. 61
27894165 2017
24
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. 61
27367496 2016
25
A prediction model of survival for patients with bone metastasis from uterine corpus cancer. 61
27655906 2016
26
Hysterectomy for Uterine Cancer in the Elderly: A Comparison Between Laparoscopic and Robot-Assisted Techniques. 61
27648646 2016
27
Lymphovascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases? 61
27261326 2016
28
Genitofemoral neuropathy after pelvic lymphadenectomy in patients with uterine corpus cancer. 61
25486104 2015
29
Trends in gynecologic cancer mortality in East Asian regions. 61
25045429 2014
30
Comorbidity is an independent prognostic factor in women with uterine corpus cancer: a nationwide cohort study. 61
24443826 2014
31
A prospective study of gynecological cancer risk in relation to adiposity factors: cumulative incidence and association with plasma adipokine levels. 61
25115836 2014
32
Concurrent Malignant Solitary Fibrous Tumor Arising from the Omentum and Grade 3 Endometrial Endometrioid Adenocarcinoma of the Uterus with p53 Immunoreactivity. 61
25114818 2014
33
Grave outcome of granulocyte colony-stimulating factor-producing endometrial cancer: a case report and literature review. 61
23279043 2013
34
Treg cells in different forms of uterine cancer. 61
23178746 2013
35
State-level uterine corpus cancer incidence rates corrected for hysterectomy prevalence, 2004 to 2008. 61
23125334 2013
36
Synchronous primary corpus and ovarian cancer: High incidence of endometriosis and thrombosis. 61
22970036 2012
37
[Epidemiology of uterine corpus cancer in some cancer registering areas of China from 2003 - 2007]. 61
22932112 2012
38
[Uterine corpus cancer: dynamics of morbidity, mortality and survival]. 61
22888648 2012
39
Endometrioid adenocarcinoma with high-grade transformation with serous and choriocarcinomatous differentiation - a case report. 61
22211141 2012
40
[Diaphragmatic metastasis from uterine corpus cancer]. 61
21842675 2011
41
Efficacy of para-aortic lymphadenectomy in early-stage endometrioid uterine corpus cancer. 61
21136177 2011
42
Comparative performance of the 2009 International Federation of Gynecology and Obstetrics' staging system for uterine corpus cancer. 61
21508766 2011
43
Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer. 61
21705925 2011
44
The value of MR imaging when the site of uterine cancer origin is uncertain. 61
21212371 2011
45
A retrospective analysis of postoperative complications with or without para-aortic lymphadenectomy in endometrial cancer. 61
21270621 2011
46
Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. 61
20966700 2010
47
Evaluation of FDG-PET for detecting lymph node metastasis in uterine corpus cancer. 61
20944170 2010
48
Current status in the management of uterine corpus cancer in Korea. 61
20922137 2010
49
Cervical, uterine corpus, and ovarian cancer mortality in Greece during 1980 to 2005: a trend analysis. 61
20686368 2010
50
Metabolic syndrome and endometrial carcinoma. 61
20219764 2010

Variations for Uterine Corpus Cancer

Copy number variations for Uterine Corpus Cancer from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 162862 22 22706138 22714284 Decreasing copy number GSTT1 Corpus uteri cancer

Expression for Uterine Corpus Cancer

Search GEO for disease gene expression data for Uterine Corpus Cancer.

Pathways for Uterine Corpus Cancer

Pathways related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 U2AF1 TP53 PTEN PPP2R1A MYC H2AC18
2
Show member pathways
13.88 TP53 PTEN PPP2R1A MYC KRAS HRAS
3
Show member pathways
13.61 TP53 PPP2R1A PIK3CA MYC KRAS HRAS
4
Show member pathways
13.52 TP53 PTEN PPP2R1A PIK3CA KRAS HRAS
5
Show member pathways
13.43 TP53 PPP2R1A PIK3CA MYC KRAS HRAS
6
Show member pathways
13.27 TP53 PPP2R1A PIK3CA MYC KRAS HRAS
7
Show member pathways
13.01 TP53 PIK3CA MYC KRAS HRAS CTNNB1
8
Show member pathways
12.97 PTEN PIK3CA KRAS HRAS ERBB2 CTNNB1
9
Show member pathways
12.94 TP53 PTEN PPP2R1A PIK3CA MYC KRAS
10
Show member pathways
12.9 TP53 PTEN MYC H2AC18 ESR1 BRCA1
11
Show member pathways
12.88 TP53 PTEN MYC KRAS HRAS ERBB2
12
Show member pathways
12.87 TP53 PTEN PIK3CA MYC KRAS HRAS
13 12.86 TP53 PTEN PIK3CA MYC KRAS HRAS
14
Show member pathways
12.84 PTEN PIK3CA MYC KRAS HRAS
15 12.83 TP53 MYC KRAS HRAS ERBB2
16
Show member pathways
12.83 TP53 PTEN PPP2R1A PIK3CA KRAS HRAS
17
Show member pathways
12.77 TP53 PIK3CA MYC KRAS HRAS
18
Show member pathways
12.77 TP53 POLE MYC FBXW7 ESR1 BRCA1
19
Show member pathways
12.76 TP53 PTEN PIK3CA KRAS HRAS ESR1
20
Show member pathways
12.71 TP53 PTEN PIK3CA KRAS HRAS ESR1
21
Show member pathways
12.69 TP53 PIK3CA MYC KRAS HRAS ERBB2
22
Show member pathways
12.61 TP53 PTEN PIK3CA KRAS HRAS ERBB2
23
Show member pathways
12.57 TP53 PTEN PIK3CA MYC KRAS HRAS
24
Show member pathways
12.56 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
25 12.55 TP53 PTEN PIK3CA MYC MIR10B KRAS
26
Show member pathways
12.54 PTEN PIK3CA MYC KRAS HRAS ESR1
27
Show member pathways
12.52 PIK3CA KRAS HRAS ESR1 CTNNB1 BRCA1
28
Show member pathways
12.49 PTEN PIK3CA MYC KRAS HRAS
29
Show member pathways
12.48 TP53 PTEN PIK3CA MYC HRAS
30
Show member pathways
12.47 TP53 PTEN MYC KRAS HRAS CTNNB1
31
Show member pathways
12.46 PIK3CA KRAS HRAS ERBB2 CTNNB1
32 12.45 TP53 PTEN PIK3CA MYC KRAS HRAS
33
Show member pathways
12.44 TP53 PTEN MYC BRCA1
34
Show member pathways
12.43 TP53 PTEN PIK3CA HRAS ERBB2 CTNNB1
35
Show member pathways
12.41 PIK3CA MYC KRAS HRAS ERBB2 CTNNB1
36
Show member pathways
12.39 PIK3CA MYC HRAS CTNNB1
37 12.39 TP53 PIK3CA KRAS HRAS CHD4
38
Show member pathways
12.38 PIK3CA HRAS ESR1 ERBB2
39
Show member pathways
12.38 PIK3CA KRAS HRAS ERBB2
40
Show member pathways
12.36 TP53 PTEN PIK3CA MYC KRAS HRAS
41
Show member pathways
12.34 PPP2R1A PIK3CA KRAS HRAS
42
Show member pathways
12.33 TP53 PTEN PIK3CA MYC KRAS HRAS
43
Show member pathways
12.3 TP53 PPP2R1A MYC CTNNB1
44 12.26 TP53 MYC KRAS CTNNB1
45 12.26 TP53 PTEN PIK3CA MYC KRAS HRAS
46 12.25 PTEN KRAS HRAS ERBB2
47
Show member pathways
12.24 TP53 PIK3CA KRAS HRAS
48 12.23 PIK3CA MYC KRAS HRAS CTNNB1
49 12.22 TP53 PIK3CA MYC MIR10B KRAS HRAS
50
Show member pathways
12.21 TP53 MYC KRAS HRAS

GO Terms for Uterine Corpus Cancer

Cellular components related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.93 U2AF1 TP53 PTEN POLE MYC HRAS
2 perinuclear region of cytoplasm GO:0048471 9.73 S100A6 PIK3CA HRAS FBXW7 ERBB2 CTNNB1
3 nucleus GO:0005634 9.53 U2AF1 TP53 S100A6 PTEN PPP2R1A POLE
4 protein-containing complex GO:0032991 9.5 TP53 MYC FBXW7 ESR1 CTNNB1 CHD4

Biological processes related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.15 TP53 MYC ESR1 ERBB2 CTNNB1 CHD4
2 cellular response to DNA damage stimulus GO:0006974 9.99 TP53 POLE MYC FBXW7 BRCA1
3 positive regulation of transcription, DNA-templated GO:0045893 9.97 TP53 MYC ESR1 CTNNB1 BRCA1 ARID1A
4 heart development GO:0007507 9.87 TP53 PTEN ERBB2 CTNNB1
5 Ras protein signal transduction GO:0007265 9.73 TP53 KRAS HRAS
6 positive regulation of cell proliferation GO:0008284 9.73 PTEN MYC KRAS HRAS ERBB2 CTNNB1
7 negative regulation of gene expression GO:0010629 9.72 TP53 HRAS FBXW7 ESR1 CTNNB1
8 positive regulation of epithelial cell proliferation GO:0050679 9.7 MYC HRAS ERBB2
9 positive regulation of MAP kinase activity GO:0043406 9.69 KRAS HRAS ERBB2
10 cellular response to UV GO:0034644 9.65 TP53 MYC FBXW7
11 positive regulation of fibroblast proliferation GO:0048146 9.63 S100A6 MYC ESR1
12 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.58 TP53 ESR1
13 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.58 TP53 ESR1
14 embryonic organ development GO:0048568 9.58 TP53 POLE CTNNB1
15 protein deubiquitination GO:0016579 9.55 TP53 PTEN MYC ESR1 BRCA1
16 response to isolation stress GO:0035900 9.54 KRAS HRAS
17 phosphatidylinositol 3-kinase signaling GO:0014065 9.54 PTEN PIK3CA ERBB2
18 cellular response to indole-3-methanol GO:0071681 9.43 CTNNB1 BRCA1
19 positive regulation of gene expression GO:0010628 9.23 TP53 PTEN MYC KRAS HRAS ERBB2
20 vasculature development GO:0001944 9.13 PIK3CA FBXW7 CTNNB1

Molecular functions related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.63 TP53 S100A6 POLE ESR1 CHD4 BRCA1
2 enzyme binding GO:0019899 9.35 TP53 PTEN ESR1 CTNNB1 BRCA1
3 transcription factor binding GO:0008134 9.02 TP53 MYC ESR1 CTNNB1 CHD4

Sources for Uterine Corpus Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....